Singapore markets close in 4 hours 12 minutes

Kintara Therapeutics, Inc. (KTRA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1680+0.0110 (+7.01%)
At close: 04:00PM EDT
0.1841 +0.02 (+9.58%)
After hours: 07:59PM EDT

Kintara Therapeutics, Inc.

9920 Pacific Heights Blvd
Suite 150
San Diego, CA 92121
United States
858 350 4364

Full-time employees2

Key executives

NameTitlePayExercisedYear born
Mr. Robert E. Hoffman B.B.A., CPAPresident, CEO, Interim CFO & Chairman of the Board767.98kN/A1966
Mr. Jeffrey A. Bacha B.Sc., M.B.A.FounderN/AN/A1968
Mr. Greg A. JohnsonActing Head of OperationsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Corporate governance

Kintara Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.